| |
High HCV Reinfection Rates Reported in HIV+, MSM (25%),
IDUs at EASL: multiple reinfections reported
|
| |
| |
from Jules: here are key reinfection studies at EASL 2016 in April in Barcelona
A study just published May 5th reported an 11% reinfection rate in IDUs in Sweden was reported from an analysis of 138 patients.
"The risk of reinfection is often cited as a reason for not offering treatment to current and former people who inject drugs (PWID)." ....."Urgently need prevention strategies"...."Importance of rapid identification and treatment to prevent transmission of HCV & HIV....suggest 3-6 month testing with HCV RNA PCR after initial infection and every 3 months after a HCV reinfection"....."Treatment should occur in concert with education and harm minimisation strategies to reduce high-risk behaviours, prevent recurrence and ongoing transmission. HCV treatment-as-prevention strategies will be enhanced by early diagnosis and increased treatment uptake in recently acquired HCV."
EASL: Hepatitis C virus reinfection incidence and outcomes among HIV-positive MSM in Western Europe - (04/15/16)....-Substantial HCV reinfection risk among HIV/HCV coninfected MSM – 7.6/100 py with 25% reinfected at 3 years.....out of 606 patients in the study 149 were reinfected at an average of 1.8 years of follow-up, and there were patients who were rein feted 2/3/4 times
.....Recent meta-anlysis estimate of prevalence of active HCV among HIV-positive MSM of 4.9-5.9%.....-Sexually transmitted but associated with high-risk sexual practices and drug use
EASL: C-EDGE CO-STAR: Favorable Impact of Elbasvir and Grazoprevir on Health-Related Quality of Life in Treatment-NaÏve HCV-Infected Persons Who Inject Drugs Receiving Opioid Agonist Therapy - (04/28/16)
2 more Re-Infection Studies:
EASL: C-EDGE CO-STAR: Efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 12 Weeks in HCV-infected Persons Who Inject Drugs on Opioid Agonist Therapy- (04/28/16).....6 "probable" reinfections out of 296 treated occurred.... The incidence of reinfection through FW24 was 3.4 reinfections per 100 person-years (Table 2)....of note, "Five of the 6 reinfections were detected at 8 weeks following completion of treatment (Figure 5)
EASL: INCIDENCE OF HCV REINFECTION AMONG TREATED INDIVIDUALS WITH RECENTLY ACQUIRED INFECTION ....MSM & IDUs, HIV+ - (04/20/16) ....Urgently need prevention strategies
High reinfection incidence following treatment for recently acquired HCV in individuals with ongoing high-risk behaviour emphasises the need for post-treatment surveillance
Of 115 participants enrolled, 84 treated participants were suitable for initial analysis (Figure 1). An end-of-treatment response (ETR) was documented in 71 (85%). HCV RNA recurrence was observed in 22 (31%), confirmed by sequencing as relapse in 17 (excluded from subsequent analysis) and reinfection in 5. ......All cases of reinfection following treatment for recently acquired HCV occurred in HIV-positive MSM, with IDU reported at end of and/or post treatment in the majority.
The risk of reinfection is often cited as a reason for not offering treatment to current and former people who inject drugs (PWID). Few studies have evaluated the incidence of HCV reinfection following treatment of recently acquired HCV infection. The aim of this analysis was to investigate the epidemiological, virological and clinical characteristics of HCV reinfection among individuals with recently acquired HCV infection
EASL: On-Treatment Illicit Drug Use Did Not Impact Treatment Outcome During Therapy With Ledipasvir/Sofosbuvir With or Without Ribavirin in the Phase 3 ION-1 Study - (04/29/16) mostly marijuana
|
|
| |
| |
|
|
|
